XFOR compared with SLDB: revenue, margins and what each company keeps, and the suppliers and customers both name

XFORX4 Pharmaceuticals, Inc

Mkt capRevenueRevenue

SLDBSolid Biosciences Inc.

Mkt capRevenueRevenue

Compare

XFORX4 Pharmaceuticals, Inc

SLDBSolid Biosciences Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

XFOR

No earnings history for XFOR.

SLDB

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q1 FY26±75.6%▲+18.81%×0.25

Q3 FY25±38.3%▼−15.29%×0.40

Feb 18 '25±29.3%▲+31.51%×1.08

Jan 8 '24±15.0%▲+7.59%×0.51

= impliedXFOR realized, solidSLDB realized, hatchedOne scale, both sides: full bar = 76%× = |realized| ÷ impliedSource: market data

XFORX4 Pharmaceuticals, Inc

3.15· pre 3.15· delayed

Mkt cap$314.3MRevenue$9MQ2 FY26Revenue$35MFY25

SLDBSolid Biosciences Inc.

6.29· pre 6.29· delayed

Pre-marketNov 3 '26delayed

Mkt cap$643.4MRevenue—Revenue—

Compare

Pre-marketNov 3 '26delayed

XFORX4 Pharmaceuticals, Inc

SLDBSolid Biosciences Inc.

3.15pre 3.15delayed

Price

6.29pre 6.29delayed

$314.3M

Mkt cap

$643.4M

Q2 FY26$9M

Revenue

—

FY25$35M

Revenue

—

XFOR3.15vsSLDB6.29Pre-marketNov 3 '26delayed